Clinical Trial Update: An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study [Phase 1, Phase 2]

View source ↗

Summary

An extension study of idelalisib (GS-1101) in subjects who benefited from prior idelalisib therapy; study terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Idelalisib (idelalisib)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-08-28